United Therapeutics Corporation (NASDAQ:UTHR) Stock Rated “Moderate Buy” by Wall Street Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has been assigned an average recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $676.40.

A number of research firms recently weighed in on UTHR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $850.00 price target on shares of United Therapeutics in a report on Monday, October 26th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Raymond James Financial set a $720.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 4th. Jefferies Financial Group restated a “buy” rating and set a $728.00 target price on shares of United Therapeutics in a research note on Wednesday, October 14th. Finally, The Goldman Sachs Group reiterated a “sell” rating and issued a $368.00 price target on shares of United Therapeutics in a research note on Thursday, October 15th.

United Therapeutics Price Performance

NASDAQ UTHR opened at $595.66 on Thursday. The business’s 50-day simple moving average is $538.56 and its 200-day simple moving average is $535.20. United Therapeutics has a 1-year low of $452.44 and a 1-year high of $614.23. The firm has a market capitalization of $25.37 billion, a P/E ratio of 22.48, a P/E/G ratio of 3.94 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The company had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $7.16 EPS. On average, equities research analysts expect that United Therapeutics will post 24.90 EPS for the current fiscal year.

United Therapeutics announced that its Board of Directors has authorized a share repurchase plan on Thursday, October 22nd that allows the company to repurchase $2 billion in outstanding shares. This buyback authorization allows the biotechnology company to buy up to 8.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Recent United Therapeutics Headlines

Here are a few of the latest headlines about UTHR:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target, above the share price cited in the background. Its forecasts call for EPS to rise from $27.46 in FY2026 to $53.67 in FY2030, signaling confidence in longer-term earnings growth. HC Wainwright coverage report
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares on November 6 and another 9,500 shares across transactions on November 9. Director Christopher Patusky also sold 1,210 shares, reducing his position by 36.12%. Insider selling can weigh on sentiment, although both executives retain shares. SEC filing

Insiders Place Their Bets

In other United Therapeutics news, Director Christopher Patusky sold 1,210 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $580.00, for a total value of $701,800.00. Following the transaction, the director directly owned 2,140 shares of the company’s stock, valued at $1,241,200. This represents a 36.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine Rothblatt sold 1,614 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $584.59, for a total value of $943,528.26. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $189,666,133.37. This trade represents a 0.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 412,238 shares of company stock worth $220,071,746 in the last three months. 8.60% of the stock is owned by insiders.

Institutional Trading of United Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Arjuna Capital grew its holdings in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares in the last quarter. Abacus Wealth Partners LLC lifted its position in shares of United Therapeutics by 5.6% during the third quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 21 shares during the last quarter. Sage Rhino Capital LLC lifted its position in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its position in shares of United Therapeutics by 5.4% during the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in United Therapeutics by 2.1% in the third quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock worth $625,000 after purchasing an additional 24 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.